AGLE stock forecast
Our latest prediction for Aeglea Biotherapeutics, Inc.'s stock price was made on the June 14, 2019 when the stock price was at 6.18$.
In the short term (2weeks), AGLE's stock price should outperform the market by 3.46%. During that period the price should oscillate between -7.05% and +10.35%.
In the medium term (3months), AGLE's stock price should outperform the market by 2.88%. During that period the price should oscillate between -17.62% and +30.45%.Get email alerts
About Aeglea Biotherapeutics, Inc.
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -2.23$ per share.
The book value per share is 3.33$
Three months stock forecastJune 14, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|